Trial Information

Summary: Wet Age-Related Macular Degeneration (AMD) Studies.

The Department of Ophthalmology is committed to participating in clinical research to ensure our patients have access to the newest treatment options. We are currently enrolling patients in clinical trials for wet age-related macular degeneration, diabetic retinopathy, and glaucoma.

Age-Related Macular Degeneration Studies
IRB-HSR # 13308: A Phase 3, Randomized, Double-Masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis Compared With Lucentis Monotherapy Every 4 Weeks in Patients with Exudative Age-Related Macular Degeneration (AMD)

The purpose of this 24 month study is to compare the safety and effectiveness of the investigational drug, bevasiranib, given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD.

Key Eligibility Criteria:
1. At least 50 years of age
2. Confirmed diagnosis of wet-AMD
3. Visual acuity between 20/40 and 20/320
4. Received no prior treatment with anti-VEGF agents (i.e. Avastin®, Lucentis®, Macugen®) in the study eye

For more information about this study please contact the Clinical Research Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu .

The principal investigator is Brian P. Conway, M.D.



www.healthsystem.virginia.edu/clinical_trials

If you would like to learn more about participating in this study, please send an e-mail message using the form below.